CTI is developing medicines to help treat your cancer while maintaining your quality of life.
Pixantrone is marketed by CTI in the EU as Pixuvri®.Summary of Product Characteristics and Package Insert
Learn about our potential treatments for non-Hodgkin Lymphoma.See Phase 3 Pipeline
Learn about our potential treatments for Acute Myeloid Leukemia (AML), Myelodysplasia (MDS).See Phase 1 Pipeline
German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRIŽ (pixantrone)
Cell Therapeutics to Present at Upcoming Investor Conferences
PIXUVRI is the only medicine approved as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell lymphomas in the E.U.
Pixantrone is marketed in the E.U. as PIXUVRI | Learn more
Our late-stage development pipeline addresses a full complement of blood-related cancers.learn about our oncology pipeline